Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome
dc.contributor.author | Shneider, Benjamin L. | |
dc.contributor.author | Spino, Catherine A. | |
dc.contributor.author | Kamath, Binita M. | |
dc.contributor.author | Magee, John C. | |
dc.contributor.author | Ignacio, Rosalinda V. | |
dc.contributor.author | Huang, Suiyuan | |
dc.contributor.author | Horslen, Simon P. | |
dc.contributor.author | Molleston, Jean P. | |
dc.contributor.author | Miethke, Alexander G. | |
dc.contributor.author | Kohli, Rohit | |
dc.contributor.author | Leung, Daniel H. | |
dc.contributor.author | Jensen, M. Kyle | |
dc.contributor.author | Loomes, Kathleen M. | |
dc.contributor.author | Karpen, Saul J. | |
dc.contributor.author | Mack, Cara | |
dc.contributor.author | Rosenthal, Philip | |
dc.contributor.author | Squires, Robert H. | |
dc.contributor.author | Baker, Alastair | |
dc.contributor.author | Rajwal, Sanjay | |
dc.contributor.author | Kelly, Deirdre | |
dc.contributor.author | Sokol, Ronald J. | |
dc.contributor.author | Thompson, Richard J. | |
dc.date.accessioned | 2022-08-02T18:55:34Z | |
dc.date.available | 2023-09-02 14:55:31 | en |
dc.date.available | 2022-08-02T18:55:34Z | |
dc.date.issued | 2022-08 | |
dc.identifier.citation | Shneider, Benjamin L.; Spino, Catherine A.; Kamath, Binita M.; Magee, John C.; Ignacio, Rosalinda V.; Huang, Suiyuan; Horslen, Simon P.; Molleston, Jean P.; Miethke, Alexander G.; Kohli, Rohit; Leung, Daniel H.; Jensen, M. Kyle; Loomes, Kathleen M.; Karpen, Saul J.; Mack, Cara; Rosenthal, Philip; Squires, Robert H.; Baker, Alastair; Rajwal, Sanjay; Kelly, Deirdre; Sokol, Ronald J.; Thompson, Richard J. (2022). "Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome." Hepatology Communications (8): 1922-1933. | |
dc.identifier.issn | 2471-254X | |
dc.identifier.issn | 2471-254X | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173065 | |
dc.description.abstract | There is growing interest in, but limited data about, intestinal bile acid transport inhibitors as treatment for cholestatic liver disease. The current analyses combine two similar randomized placebo-controlled trials with subsequent extension phases investigating the impact of maralixibat in children with severe cholestasis secondary to Alagille Syndrome (n = 57). The primary outcomes were measures of pruritus (ItchRO[Obs]) and clinician scratch scale (CSS), both increasing in severity from 0 to 4) and quality of life (QoL) (Parent PedsQL and Multidimensional Fatigue Scale module [MFS] scaled 0–100 with increased QoL) at week 48 of the extension phase relative to the baseline of the placebo-controlled trials (week 13). Secondary assessments included other clinical and biochemical parameters assessed in participants at week 72 or end of treatment (after week 48). At week 48, statistically and clinically significant least square mean (95% CI) improvements in pruritus and QoL were observed (ItchRO[Obs] −1.59 [−1.81, −1.36], CSS −1.36 [−1.67, −1.05], PedsQL +10.17 [4.48, 15.86], and multidimension fatigue [MFS] +13.97 [7.85, 20.08]). At week 48, serum bile acids, platelet count, and cholesterol decreased, whereas alanine aminotransferase (ALT) increased and total bilirubin (TB) and albumin were stable. Changes were durable at week 72 and end of treatment. There were no deaths; 2 participants underwent liver transplantation. Study drug was discontinued in 9 participants after treatment-emergent adverse events, 6 of which were events of increased ALT or TB. Conclusion: Maralixibat administration was associated with marked improvement in pruritus and QoL. Interpretation of these findings is complicated by the complex natural history of severe cholestasis in Alagille syndrome.Potential attribution of an impact of maralixibat or other IBATi on disease progression in pediatric cholestasis may require continued long-term follow-up of individuals receiving IBATi and a relevant contemporaneous natural history cohort. Future investigations of IBATi in cholestatic liver disease may need to delineate the mechanisms of action including effects on bile acid composition, the intestinal microbiome and the gut-liver axis. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173065/1/hep41992-sup-0001-AppendixS1.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173065/2/hep41992.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173065/3/hep41992-sup-0002-AppendixS2.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173065/4/hep41992-sup-0003-AppendixS3.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173065/5/hep41992_am.pdf | |
dc.identifier.doi | 10.1002/hep4.1992 | |
dc.identifier.source | Hepatology Communications | |
dc.identifier.citedreference | Dull MM, Kremer AE. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep. 2019; 21: 48. | |
dc.identifier.citedreference | Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of alagille syndrome. J Pediatr Gastroenterol Nutr. 2018; 67: 148 – 56. | |
dc.identifier.citedreference | Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, et al. Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials. Drug Saf. 2021; 44: 619 – 34. | |
dc.identifier.citedreference | Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology. 2016; 151: 1046 – 51. | |
dc.identifier.citedreference | Mirum Pharmaceuticals Inc. Livmarli prescribing information. Foster City, CA; 2021. | |
dc.identifier.citedreference | Kamath BM, Abetz-Webb L, Kennedy C, Hepburn B, Gauthier M, Johnson N, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient. 2018; 11: 69 – 82. | |
dc.identifier.citedreference | Shneider BL, Spino C, Kamath BM, Magee JC, Bass LM, Setchell KD, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome. Hepatol Commun. 2018; 2: 1184 – 98. | |
dc.identifier.citedreference | Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020; 40: 1812 – 22. | |
dc.identifier.citedreference | Wang KS, Tiao G, Bass LM, Hertel PM, Mogul D, Kerkar N, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology. 2017; 65: 1645 – 54. | |
dc.identifier.citedreference | Kamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, et al. Outcomes of childhood cholestasis in alagille syndrome: results of a multicenter observational study. Hepatol Commun. 2020; 4: 387 – 98. | |
dc.identifier.citedreference | Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020; 51: 90 – 109. | |
dc.identifier.citedreference | Shneider BL, Kamath BM, Magee JC, Goodrich NP, Loomes KM, Ye W, et al. for the Childhood Liver Disease Research Network (ChiLDReN). Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases—Examination of cholestatic liver disease in Alagille syndrome. Hepatol Commun. 2022; 1 – 12. https://doi.org/10.1002/hep4.1970 | |
dc.identifier.citedreference | Chen Y, Wang ZL, Yeo M, Zhang QJ, Lopez-Romero AE, Ding HP, et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology. 2021; 161: 301 – 317.e16. | |
dc.identifier.citedreference | Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021; 398: 1581 – 92. | |
dc.identifier.citedreference | Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019; 3: 365 – 81. | |
dc.identifier.citedreference | Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017; 389: 1114 – 23. | |
dc.identifier.citedreference | Schoch D, Sommer R, Augustin M, Stander S, Blome C. Patient-reported outcome measures in pruritus: a systematic review of measurement properties. J Invest Dermatol. 2017; 137: 2069 – 77. | |
dc.identifier.citedreference | Bartels DJ, van Laarhoven AI, van de Kerkhof PC, Evers AW. Placebo and nocebo effects on itch: effects, mechanisms, and predictors. Eur J Pain. 2016; 20: 8 – 13. | |
dc.identifier.citedreference | Merz M, Lee KR, Kullak-Ublick GA, Brueckner A, Watkins PB. Methodology to assess clinical liver safety data. Drug Saf. 2014; 37 ( (Suppl 1) ): S33 – 45. | |
dc.identifier.citedreference | Shneider BL, Magee JC, Bezerra JA, Haber B, Karpen SJ, Raghunathan T, et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics. 2012; 130: e607 – 14. | |
dc.identifier.citedreference | Kamath BM, Spino C, McLain R, Magee JC, Fredericks EM, Setchell KD, et al. Unraveling the relationship between itching, scratch scales, and biomarkers in children with alagille syndrome. Hepatol Commun. 2020; 4: 1012 – 8. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.